Linked Life Data

12197225

Source:http://linkedlifedata.com/resource/pubmed/id/12197225

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5-6
pubmed:dateCreated
2002-8-28
pubmed:abstractText
Pegylated-liposomal doxorubicin (Doxil) is a form of liposomal doxorubicin in which the liposomes are coated with methoxypoly(ethylene glycol), resulting in a diminished uptake by the reticuloendothelial system, a longer half-life in blood, and a different toxicity profile than nonpegylated liposomes. A phase II study of Doxil in mesothelioma was performed. The initial dose per course was 55 mg/m2 every 4 weeks with dose modification based on mucositis and hand-foot syndrome (the main limiting toxicities). Treatment was generally well tolerated. Of 73 evaluable treatment courses in 15 patients, toxicities were mild and similar to previous reports, but dose reduction was common. No definite cardiac toxicity was observed. Fourteen patients were evaluable for response; four of the 15 patients treated responded meaningfully. These data suggest that pegylated-liposomal doxorubicin has activity in mesothelioma, and that this treatment is associated with modest toxicity.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0735-7907
pubmed:author
pubmed:issnType
Print
pubmed:volume
20
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
693-9
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
Phase II trial of pegylated-liposomal doxorubicin (Doxil) in mesothelioma.
pubmed:affiliation
University of Minnesota Medical School, Masonic Cancer Center, Minneapolis, MN 55455, USA.
pubmed:publicationType
Journal Article, Clinical Trial, Clinical Trial, Phase II